Researchers found that Singapore’s Health Sciences Authority has approved the ACAM2000® vaccine for preventing mpox disease in adults at high risk. This expanded use of the vaccine, which was initially approved for smallpox, aims to bolster public health efforts during mpox outbreaks, particularly when alternative vaccines are not available.

For individuals concerned about aging well, this development could be significant. Mpox can cause severe health complications, and being vaccinated may help protect those at higher risk, such as healthcare workers or individuals in close contact with infected persons. The vaccine is administered as a single dose using a bifurcated needle, which makes it relatively easy to distribute in emergency situations.

The evidence supporting this approval includes existing human safety data and results from a controlled animal study that demonstrated the vaccine’s effectiveness against mpox. However, while this approval is a positive step, it is important to note that the vaccine’s safety profile includes potential serious side effects, such as myocarditis and skin infections, particularly in individuals with certain health conditions. Therefore, it is crucial for people to consult healthcare professionals regarding their vaccination options based on their personal health circumstances.

If you are in a high-risk category for mpox, consider discussing the benefits and risks of the ACAM2000® vaccine with your healthcare provider. Staying informed about vaccinations can be a key part of maintaining your health as you age.

Source: globenewswire.com